Kidney Cancer Drugs Market size is estimated at USD 6.9 billion in 2024 and is expected to exceed USD 13.46 billion by the end of 2037, expanding at over 5.5% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of kidney cancer drugs is evaluated at USD 7.09 billion.
The primary growth driver of the kidney cancer drugs market is the increasing incidence of kidney cancer worldwide. As the number of diagnosed cases rises, a huge demand for effective treatments fuels demand for new and improved therapies. According to a 2024 report by the National Library of Medicine, kidney cancer (renal cancer) is a disease with an increasing global incidence of 400000 new cases per year and a mortality rate of approximately 175000 deaths per year.
Moreover, kidney cancer drug manufacturers are investing heavily in research and development activities for the production of innovative solutions. Companies investing in R&D are able to develop new drugs and therapies, including targeted treatments, immunotherapies, and combination therapies. These innovations address unmet medical needs and offer improved efficacy, safety, and convenience, expanding the range of available treatment options. For instance, Merck & Co's R&D investment strategy focuses on immuno-oncology, notably the development of its portfolio following the success of its popular cancer treatment, Keytruda (pembrolizumab).
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.5% |
|
Base Year Market Size (2024) |
USD 6.9 billion |
|
Forecast Year Market Size (2037) |
USD 13.46 billion |
|
Regional Scope |
|
Pharmacological Class Type (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokinesis, Others (Immune Checkpoint Inhibitors, CTLA-4 Inhibitors, and Antimetabolites))
Angiogenesis inhibitors segment is anticipated to account for kidney cancer drugs market share of more than 53.0% by the end of 2037. Angiogenesis inhibitors are divided into two types, one that directly affects microvascular endothelial cells recruited by the tumor, and another that directly targets tumor growth factors. Angiogenesis inhibitors called anti-angiogenic therapy are effective in the treatment of kidney cancer. For instance, angiogenesis inhibitors such as bevacizumab (Avastin) and tyrosine kinase inhibitors (TKIs) which include sunitinib (Sutent) and pazopanib (Votrient), have demonstrated efficacy in treating renal cell carcinoma by blocking the formation of new blood vessels that tumors require to thrive. Angiogenesis inhibitors show positive results when combined with immunotherapy and chemotherapy.
Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy)
Targeted therapy is estimated to hold a dominant kidney cancer drugs market share throughout the forecast period owing to its effective result in slowing down cancer cell formation. This therapy type is often used to treat rigorous kidney cancer types. According to the Canadian Cancer Society, targeted therapy kills cancerous cells without harming healthy cells. This precision leads to more effective treatments with potentially fewer side effects, making them an ideal option for kidney cancer patients.
The development of new targeted therapies, including tyrosine kinase inhibitors, continues to advance. For instance, Levatinib is an anti-cancer drug used in targeted therapy processes to treat cancer patients including kidney cancer. From the tyrosine kinase inhibitor medication class, levatinib shows effective results in advanced kidney cancer treatment. Pills or tablets are prime forms of medications used in targeted therapy treatment, except temsirolimus as it has an intravenous mode of consumption. These effective characteristics of targeted therapies make them the prime kidney cancer treatment type, leading to high sales of targeted therapy medications.
Our in-depth analysis of the kidney cancer drugs market includes the following segments:
|
Therapy Type |
|
|
Pharmacological Class Type |
|
|
Distribution Channel |
|
North America Market Forecast:
North America in kidney cancer drugs market is projected to dominate around 35% revenue share by the end of 2037, owing to the presence of well-developed healthcare infrastructure. The robust healthcare system facilitates the availability and accessibility of new and innovative kidney cancer drugs. Additionally, the region is a major center for clinical trials and cancer research. This fosters the development of new kidney cancer drugs and drives their availability in the market. The rising prevalence of kidney cancer cases, innovations in cancer drug formulations, and high investments in new product launches by biopharma companies are further fuelling the kidney cancer market growth in North America.
The U.S. kidney cancer drugs market size stood at USD 1.6 billion in 2023, owing to the rising cases of kidney cancer. According to the American Cancer Society, the U.S. is expected to witness around 81,600 new kidney cancer cases and more than 14,000 deaths by the end of 2024. The majority of people diagnosed with kidney cancer are estimated to be between the age group of 55 and 74. Moreover, comprehensive health insurance coverage and favorable reimbursement policies for cancer treatments facilitate patient access to expensive and innovative therapies, boosting market growth.
Canada is also advancing in the field of cancer treatment due to the presence of several kidney cancer care organizations such as Kidney Cancer Canada, Canadian Cancer Society, and Cancer Care Ontario. Canada represents a substantial market for kidney cancer drugs, with a growing focus on addressing renal cell carcinoma through advanced treatment options. The kidney cancer drugs market growth is driven by increasing incidence rates and the availability of innovative therapies. According to Canadian Cancer Society estimations, around 9,000 individuals in Canada are expected to be detected with kidney and renal pelvis cancer by the end of 2024, out of which 5900 are supposed to be males and 3100 females.
APAC Market Analysis:
The Asia Pacific in kidney cancer drugs market is anticipated to increase at a fast pace between 2025 and 2037. The rising healthcare expenditures, increasing patient pool in high-potential economies such as China and India, and growing awareness of renal cancer are expected to augment the sales of kidney cancer treatments in the region in the coming years. In India government initiatives on cancer diagnosis and care are set to uplift the profits of kidney cancer drug manufacturers. Indian Cancer Society (ICS) is actively carrying out various cancer awareness programs around the country. According to the Indian Cancer Society (ICS), the cases of cancer are increasing rapidly in India, with kidney cancer constituting 1.3% of the country’s total cancer cases.
According to the World Cancer Research Fund International, China has a high prevalence of kidney cancer across the world. In April 2024, Shanghai Junshi Biosciences Co., Ltd declared that the National Medical Products Administration approved their new drug ‘toripalimab’ for medium to high-risk unresectable or metastatic renal cell carcinoma treatment. Toripalimab in combination with axitinib is approved to be used as the first-line of treatment for renal cancer in China.
The kidney cancer drugs market is competitive owing to the strong presence of established companies and the emergence of start-ups. The key players are investing heavily in the production of advanced kidney cancer drugs market. This move is set to increase their market reach and earn high profits. Industry giants are also adopting marketing tactics such as collaboration with research institutions to develop innovative kidney cancer drugs and partnerships with other players to boost their regional expansion. New companies are focused on the development of cutting-edge kidney cancer diagnostic and therapeutic solutions to stand out in the crowd.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?